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BACKGROUND: In lung cancer CT screening, participants often have an indeterminate screening result at baseline requiring a follow-up
CT. In subjects with either an indeterminate or a negative result after screening, we investigated whether health-related quality of life
(HRQoL) changed over time and differed between groups in the short term.
METHODS: A total of 733 participants in the NELSON trial received four questionnaires: T0, before randomisation; T1, 1 week before
the baseline screening; T2, 1 day after the screening; and T3, 2 months after the screening results but before the 3-month follow-up
CT. HRQoL was measured as generic HRQoL (the 12-item Short Form, SF-12; the EuroQol questionnaire, EQ-5D), anxiety (the
Spielberger State-Trait Anxiety Inventory, STAI-6), and lung-cancer-specific distress (the Impact of Event Scale, IES). For analyses,
repeated-measures analysis of variance was used, adjusted for covariates.
RESULTS: Response to each questionnaire was 88% or higher. Scores on SF-12, EQ-5D, and STAI-6 showed no clinically relevant
changes over time. At T3, IES scores that were clinically relevant increased after an indeterminate result, whereas these scores
showed a significant decrease after a negative result. At T3, differences in IES scores between the two baseline result groups were
both significant and clinically relevant (Po0.01).
CONCLUSION: This longitudinal study among participants of a lung cancer screening programme showed that in the short term
recipients of an indeterminate result experienced increased lung-cancer-specific distress, whereas the HRQoL changes after a
negative baseline screening result may be interpreted as a relief.
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Lung cancer is the main cause of cancer-related deaths worldwide
among men and women (Ferlay et al, 2004; American Cancer
Society, 2007). Although cancer can be detected in an early
stage by computed tomography (CT) screening (Henschke et al,
2006), results from randomised controlled trials are needed
before deciding whether CT screening will reduce lung cancer
mortality, and whether implementation of large-scale lung cancer
CT screenings programmes should be recommended (Gohagan
et al, 2004; Bach et al, 2007; van Iersel et al, 2007; Field and Duffy,
2008).
Most CT screening studies report baseline rates of 14–43%
of non-calcified nodules (5–10mm in diameter); this relatively
large range is attributed to geographic differences in nodule
prevalence and the slice thickness used (Diederich et al, 2002;
Wilson et al, 2008). Subjects with this type of nodule
usually receive a recommendation to undergo a follow-up CT
3–4 months later to assess whether a nodule has grown, because
nodule growth is associated with increased cancer risk
(Swensen et al, 2005).
In the Dutch–Belgian randomised controlled trial for lung
cancer screening in high-risk subjects (the NELSON trial), subjects
could receive either a negative, an indeterminate, or a positive scan
result (Xu et al, 2006). Subjects receiving an indeterminate scan
result at baseline were invited to undergo a follow-up scan 3
months later; however, receiving such a result and waiting for this
scan might have an unfavourable effect on health-related quality of
life (HRQoL), compared with receiving a negative result. For
example, in the PLuSS study, a significant increase of generic
anxiety was found 1–2 weeks after communication of an
indeterminate baseline screening result (Byrne et al, 2008).
However, Byrne et al (2008) used HRQoL instruments that
precluded detailed evaluation of the psychological consequences
of lung cancer screening; moreover, possible changes in
HRQoL between the baseline test result and the 3-month
follow-up scan result were not reported. Furthermore, a study
on breast cancer screening showed that anxiety was higher
just before screening, compared to basic HRQoL unrelated to
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screening (Rijnsburger et al, 2004). So, to determine the whole
effect of screening, it is important to establish whether HRQoL is
already negatively affected just before baseline screening.
In this study we assessed changes in generic and lung-cancer-
specific HRQoL changes over time among participants undergoing
lung cancer screening in the short term. Therefore, we addressed
the following questions: (1) To what extent does HRQoL decrease
just before baseline screening? (2) Is there a difference in HRQoL
between those with an indeterminate baseline result and those with
a negative result? We hypothesised that lung-cancer-specific
distress scores just before baseline CT screening would be higher
compared with scores acquired a few months before screening
(Rijnsburger et al, 2004). Also, in subjects who received an
indeterminate baseline result we expected higher levels of lung-
cancer-specific distress 2 months after screening (but before the
3-month follow-up scan) compared to those who received a
negative result.
MATERIALS AND METHODS
NELSON study population
A random sample of Dutch and Belgian subjects (aged 50–75
years) registered in population registries received a questionnaire
containing items about health and smoking history. Current and
former smokers were asked to complete this ‘first’ NELSON
questionnaire. Respondents who had smoked 415 cigarettes per
day for425 years or410 cigarettes per day for430 years, those
who still smoked, or those who had quit 10 or less years ago were
invited to participate in the trial (van Iersel et al, 2007).
Informed consent was obtained from 15 822 high-risk subjects
who were subsequently randomised (1 : 1) to either a screening
group, or a control group that received no screening. Participants
in the screening group could receive either a positive, indetermi-
nate, or negative test result within 3 weeks after the baseline CT
scan was performed (Xu et al, 2006). A positive test result required
referral to a pulmonologist for work up and diagnosis.
Participants with an indeterminate result were scheduled to
undergo a follow-up CT scan 3 months later to evaluate whether
the nodule had grown. The letter to participants with an
indeterminate result stated: ‘y we have observed a very small
abnormality in your lung (5 to 10mm long). Such a small
abnormality is often detected in many persons and it usually
represents a small scar or a minor inflammation. Therefore, at
this moment there is no need for any further investigations.
However, in order to see whether there has been any change in
this abnormality, a new CT scan of the lungs will be made after
3 to 4 months.’ The letter also explains the possible results and
related work-up after this follow-up CT scan: ‘y participants with
an abnormality showing no growth will receive a negative test
result and will be invited for a CT scan 1 year after the baseline
screening. Those with an abnormality showing some growth
will be referred to a pulmonologist for further investigations’
(Xu et al, 2006).
The NELSON trial, including the current HRQoL study, was
approved by the Dutch Ministry of Health and by the local ethics
committees of the participating centres. Informed consent was
obtained from all participants. The NELSON trial is registered at
www.trialregister.nl with number ISRCTN63545820.
HRQoL study
A consecutive sample of 1466 participants was taken from the
screening centres in Haarlem and Utrecht, randomised in August
2005 (n¼ 977), September 2005 (n¼ 390), and November 2005
(n¼ 99). All participants received a questionnaire after eligibility
check, after sending the information brochure, and signing of the
informed consent form, but before trial randomisation (Time 0
(T0), baseline HRQoL assessment). Subjects randomised to the
screen arm received a second questionnaire 1 week before
the baseline scan (Time 1, T1); they were asked to complete the
questionnaire before the baseline scan was performed. At 1 day
after this baseline scan, they received a third questionnaire (Time
2, T2) and were asked to complete this questionnaire within 1
week. At T2, subjects did not receive the scan result of the baseline
scan. Finally, for subjects who had a negative or an indeterminate
test result, a questionnaire was sent about 2 months after the
baseline scan was made (Time 3, T3). For subjects with an
indeterminate scan result this was about 1 month before the
3-month follow-up scan.
In this study, the response of those who did not undergo
baseline screening, or who had a positive test result, was excluded
from the analyses. The questionnaire responses of those who
completed T1 after the CT scan (n¼ 12), who completed T2 before
the CT scan (n¼ 0) or after the baseline test result (n¼ 6), and who
completed T3 after the result of the follow-up scan (n¼ 1) were
excluded. These were not counted as responses.
Measures
Generic HRQoL The participant’s generic HRQoL was measured
with the 12-item Short Form (SF-12) and the EuroQol ques-
tionnaire (EQ-5D) (Essink-Bot et al, 1993; Ware et al, 1996;
Gandek et al, 1998; Kind et al, 2005). The SF-12 is a shorter version
of the SF-36 and consists of a physical component summary (PCS)
and a mental component summary (MCS) (Ware et al, 1996). We
used the acute (1-week recall) form of version 1. Each participant
completed the SF-12 at T0 and T3. A higher score indicates a better
HRQoL.
Respondents were also asked to rate their own health on the
visual analogue scale (VAS) of the EQ-5D, ranging from 0
(worst imaginable health status) to 100 (best imaginable health
status) (Essink-Bot et al, 1993; Kind et al, 2005). Participants
completed the EQ-5D VAS at all four assessment points (i.e. T0,
T1, T2, and T3).
Generic anxiety Generic anxiety was measured using the short
form of the Spielberger State-Trait Anxiety Inventory (STAI-6)
(van der Bij et al, 2003). Six items related to anxiety (calm, tense,
upset, relaxed, content, and worried) were rated on a four-point
scale. The total summary score was calculated in subjects with a
maximum of three missing values and could range from 20 to 80,
with higher scores indicating more anxiety (Maissi et al, 2005). The
STAI-6 is reported to have good reliability and validity, and was
found useful to evaluate the effectiveness of screening programmes
on subjective anxiety levels (van der Bij et al, 2003). The STAI-6
was used at all four assessment points.
Lung-cancer-specific distress Lung-cancer-specific distress was
measured using the Impact of Event Scale (IES) (Horowitz et al,
1979; Brom and Kleber, 1985). The 15 IES items were tailored to
lung cancer as the specific stressors. Each item was scored on a
four-point scale: not at all (score of 0), rarely (score of 1),
sometimes (score of 3), and often (score of 5). The total score and
subscales (avoidance and intrusion) were calculated for those who
completed 75% of the questions on each subscale, and were
corrected for the total number of questions on the subscale. The
total summary score could range from 0 to 75 (intrusive scale
0–35, avoidance scale 0–40), with a higher score indicating more
lung-cancer-specific distress. The IES was used at all four
assessment points.
Demographic and other data At T0, the questionnaire had items
on marital and smoking status. Educational level and smoking
pack-years were derived from the first NELSON questionnaire.
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Statistical analyses
Differences in respondent characteristics between those with a
negative or indeterminate baseline scan result were tested with
Mann–Whitney U-tests (in case of non-normally distributed
continuous variables) and w2-tests (for discrete variables). Then,
we first analysed differences in HRQol over time, focusing on
differences between the two baseline result groups. Second, the
changes in HRQoL before and after the baseline scan result were
analysed. For the latter analyses, we started by using data of the
total group in the period before the CT scan result (T0, T1, and
T2), because all subjects were still unaware of the baseline CT
result. After the CT scan result (T0–T3 and T2 and T3) the data
from the two result groups were analysed separately. For all
analyses repeated-measures analysis of variance (ANOVA) was
applied, using ‘proc mixed’ from the SAS system version 9.1 (SAS
Institute Inc., Cary, NC, USA); this allowed use of all available data,
including the incomplete records. For the subjects, we used models
with a random intercept to allow for dependence between the
repeated measurements.
Effect of baseline result on HRQoL over time Differences in
HRQoL between the negative and indeterminate result groups were
analysed at the four assessment points. The models included a
main effect for time, and for an interaction between group and
time. Time was included as a factor with four levels (one for each
assessment) to account for possible non-linearity in the change in
HRQoL scores. The following fixed covariates were added to the
model: age (because older people are reported to show less anxiety
and better mental health) (Taylor et al, 2004; Byrne et al, 2008),
gender (because women are reported to show a different fear of
cancer and have worse generic HRQoL compared with men)
(Taylor et al, 2004), education (because higher-educated lung
cancer screening participants are reported to be less anxious, have
less fear of cancer and less distress) (Byrne et al, 2008), smoking
status (because current smokers generally have a worse HRQoL
than non-smokers, and more anxiety and fear of cancer)
(Laaksonen et al, 2006), and smoking pack-years (because we
expected subjects with more pack-years to be more anxious and to
have worse health).
The IES scores were highly skewed. However, as a logistic
regression model using a generalised linear mixed models
approach analysis would limit the data, and because choosing a
cut-off point is arbitrary and use of the model in fact produced the
same results as with the repeated-measures ANOVA, we con-
sidered repeated-measures ANOVA to be appropriate for the IES
scores.
Change in HRQoL before and after receipt of baseline scan
result Before the receipt of the baseline result (T0, T1, and T2),
the same repeated-measures models as described above (adjusting
for covariates) were used for the total group, but this time
including contrasts to test differences in scores of the total group
between specific assessment points (ie T0 vs T1, and T1 vs T2, and
a model with T0 vs T2). In these models, the main effect for group,
and the interaction between group and time, was no longer
necessary and was thus excluded. After receipt of the baseline
result (T3) changes in HRQoL between T2 and T3 and between
T0 and T3 were analysed separately for the groups with a
negative and with an indeterminate baseline result. The same
repeated-measures model was used as for the analyses between
T0, T1, and T2.
A P-value o0.05 was considered statistically significant. To
provide a clue to the meaningfulness of statistically significant
differences between means at two assessments or between
subgroups, we used the minimal important difference (MID),
which is defined as half of a standard deviation (s.d.) of the mean
(Norman et al, 2003). The MID can serve as a default value for
meaningful changes in HRQoL. For changes over time the s.d. at
the first assessment of the two compared assessment points was
used, and for differences between groups the pooled s.d. of the two
groups at a specific time point was used.
RESULTS
Response and respondent characteristics
In total, 41 screen arm participants (5.6%) were excluded
from the HRQoL study because they either did not undergo
baseline screening (n¼ 30) or had a positive baseline result
(n¼ 11). In the screen group, the response to the questionnaires
was 91.0% (630 out of 692) at T0, 93.6% (641 out of 685) at T1,
93.0% (620 out of 667) at T2, and 87.7% (600 out of 684) at T3
(Figure 1). At least one of the four questionnaires was returned by
99.6% (689 out of 692) of the subjects, and 71.4% (494 out of 692)
completed all four questionnaires. The T0 questionnaire was
completed 164.8 (s.d. 107.5) days before baseline screening, and
the T1 questionnaire 2.5 (s.d. 6.5) days before baseline screening.
The T2 questionnaire was completed 4.0 (s.d. 3.3) days after
baseline screening, and the T3 questionnaire 80.2 (s.d. 20.1) days
after baseline screening. The T3 questionnaire was completed 59.4
(s.d. 24.1) days after the baseline screening result. For subjects with
an indeterminate result this was 20.1 (s.d. 16.3) days before the
follow-up scan.
Almost 50% of the respondents were men and the mean age was
about 58 years (Table 1). No statistically significant differences in
background characteristics were found between subjects with a
negative and indeterminate baseline screening results.
Effect of baseline result on HRQoL over time
At each assessment, subjects with a negative test result had better
HRQoL scores on all scales than subjects with an indeterminate
result (Table 2; Figures 2A–G). Results of the repeated-measures
analysis (adjusted for gender, age, education, smoking status, and
smoking pack-years) showed no statistically significant differences
in the SF-12 scores (MCS and PCS) between subjects with a
negative and an indeterminate result at the two assessment points
(Figures 2A and B). Also, at T0, T1, and T2 no statistically
significant differences were found in EQ-5D-VAS and STAI-6
scores between subjects with a negative and an indeterminate test
result (Figures 2C and D). At T3, compared with subjects with a
negative result, those with an indeterminate result had statistically
significantly lower scores on the EQ-5D-VAS and higher scores on
the STAI-6 (i.e. both worse), but the difference was not clinically
relevant (both P’s o0.01). At T0, T1, and T2 the IES total score
showed no statistically significant inter-group difference, whereas
at T3 the IES scores in the indeterminate result group were
statistically significant and clinically relevant higher (i.e. worse)
than in the negative result group (Po0.01) (Figures 2E–G).
In women and current smokers, scores on the PCS, EQ-5D VAS,
STAI-6, and IES showed a statistically significant difference, but
were not clinically relevant worse (i.e. they did not exceed the
MID), compared with men and former smokers (data not shown).
Change in HRQoL before and after receipt of baseline scan
result
Before the receipt of the baseline scan result, HRQoL scores on the
EQ-5D VAS, STAI-6, and IES for the total group of respondents
were statistically significantly worse at T1 (just before the baseline
CT scan) compared with those at T0 (Po0.05 for EQ-5D, rest
o 0.01) (Figures 2A–G). Between T1 and T2, there was no
statistically significant change in EQ-5D VAS scores. Average
scores on the STAI-6 and IES were statistically significantly better
at T2 (just after the CT scan) compared with T1 (all Po0.01).
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IES total scores and the IES avoidance scores did not revert to
baseline levels, as they were statistically significantly worse at T2
compared with T0 (both P’so0.05). In the total group, none of the
statistically significant changes over time exceeded the MID, thus
none of them was clinically relevant.
In the negative result group, the EQ-5D VAS and STAI-6
scores remained unchanged between T2 and T3, and between
T0 and T3. The IES scores were statistically significantly lower
(ie better) at T3 compared with T2 (all Po0.01) and also
compared with T0 (Po0.01). In the indeterminate result group,
the EQ-5D and the IES scores were worse at T3 compared with T2
(Po0.01), and compared with T0 (Po0.01). The STAI-6 scores
remained unchanged between T2 and T3, but were worse at T3
compared with T0 (Po0.05). For all statistically significant
differences in HRQoL over time, only the changes in IES scores
between T0 and T3 in the indeterminate result group were also
clinically relevant.
Impact of covariates on HRQoL
In general, the HRQoL scores were worse for women than for men
(Po0.05). Subjects with more pack-years had a worse self-reported
health (EQ-5D VAS) and had worse physical health scores (PCS)
than subjects with less pack-years (Po0.05). Current smokers had
worse HRQoL scores at all scales (Po0.05) except for the mental
health scores (MCS) than former smokers.
DISCUSSION
Lung-cancer-specific distress increased in a clinically relevant
manner 2 months after receipt of an indeterminate result of
baseline screening. After receiving the baseline CT result, subjects
with an indeterminate screening result had clinically relevant
higher lung-cancer-specific distress than subjects with a negative
result. In the groups with a negative or indeterminate result,
Randomisation
Control group Screen group
Baseline
CT scan
Test result
Negative result
Negative result
Second round
CT scan
Indeterminate
result
Positive result
Positive result
3–4-month
follow-up scan
T0 assessment
SF-12,EQ-5D,STAI-6, IES
T1 assessment
EQ-5D, STAI-6, IES
T2 assessment
EQ-5D, STAI-6, IES
T3 assessment
SF-12,EQ-5D, STAI-6, IES
Response: 630/692 = 91.0%
Response: 641/685 = 93.6%
Response: 620/667 = 93.0%
Response: 600/684 = 87.7%
Eligible subjects for the
NELSON trial who signed
the informd consent form
Figure 1 Flow chart of the HRQoL study. 41 subjects out of 733 of the screen group were excluded from the HRQoL study: 30 had no baseline CT scan,
and 11 had a positive CT result at baseline. At T1, T2, and T3 a total of 7, 25, and 8 questionnaires, respectively, were not sent due to administrative failures.
Responses at T1, T2, and T3 were excluded for 1, 2, and 2 questionnaires, respectively, due to more than 50% missing items. Also excluded were T1
questionnaires (n¼ 10) completed after the baseline CT scan, T2 questionnaires (n¼ 6) completed after the baseline CT scan result, and T3 questionnaires
(n¼ 1) completed after the follow-up scan result.
HRQoL in lung cancer CT screening
KAM van den Bergh et al
30
British Journal of Cancer (2010) 102(1), 27 – 34 & 2010 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
no clinically relevant differences over time within or between
groups were found for physical/mental/self-reported health and
generic anxiety.
In this study, the statistically significantly worse HRQoL just
before the CT scan, compared with HRQoL at a neutral point of
time before screening (T0), is similar to an earlier report on breast
cancer screening (Rijnsburger et al, 2004); however, in the latter
study it is unknown whether the self-reported health change
exceeded the MID of half an s.d. As a result of a slightly
unfavourable effect of CT scanning on HRQoL, we did not find any
clinically relevant changes between the assessment points (T0 to
T1 to T2 to T3). Nevertheless, in the indeterminate result group
there was a clinically relevant increase in lung-cancer-specific
distress when comparing T0 with T3. This implies that performing
an HRQoL assessment at a neutral point in time is important.
In our indeterminate result group, the STAI anxiety scores
showed a statistically significant increase from the baseline HRQoL
assessment up to 2 months after receipt of the baseline screening
result. Byrne et al (2008) also found a statistically significant
increase in anxiety 1–2 weeks after an indeterminate baseline
result compared with before the CT scan. However, the size of
the change was below our criterion for clinical relevance.
Re-evaluation of the reported unadjusted means in the study of
Byrne et al revealed that anxiety scores for indeterminates were
not clinically relevantly worse, which is similar to our results.
However, comparison of the results of the PLuSS study and ours
was difficult because the details of their result letter to the
participants were unknown, and the follow-up time for the
indeterminate results also differed (Xu et al, 2006; Byrne et al,
2008; Wilson et al, 2008).
Using a more specific HRQoL instrument (i.e. the IES), we could
show both a statistically significant and a clinically relevant change
from the baseline HRQoL assessment up to 2 months after the
receipt of the result, as well as a difference between our two result
groups. This implies that an indeterminate test result had at least
some negative impact on HRQoL in the period between receipt of
the test result and the follow-up scan 3–4 months later. Never-
theless, the effect was small because the average IES total score in
the indeterminate group was only 8.3 (s.d. 11.3) on a scale with an
upper limit of 75. The IES scales were also highly skewed; even in
the indeterminate result group 30% did not experience any lung-
cancer-specific distress at 2 months after screening (i.e. IES total
score¼ 0).
The HRQoL decrement should be very low in a screening
situation, because even a small HRQoL decrement due to screening
at the individual level will accumulate to a large burden at popu-
Table 1 Characteristics of the respondents at T0
Baseline scan result
Total group
(n¼ 630)
Negative
(n¼489)
Indeterminate
(n¼ 141)
P differences Negative/
Indeterminate result
Sex: male (%) 47.1 46.2 50.4 0.386a
Age in years: mean (s.d.), median 57.8 (5.5), 56.7 57.7 (5.5), 56.6 58.3 (5.6), 57.5 0.225b
Education 0.150a
1. Primary education (%) 9.3 8.9 10.8
2. Lower vocational or lower secondary general education (%) 37.9 38.3 36.7
3. Intermediate vocational or higher secondary general education (%) 25.1 23.4 30.9
4. Higher vocational education or university (%) 27.7 29.4 21.6
Marital status: Married/living with partner (%) 74.9 75.1 74.5 0.888a
Smoking
Current smokers (%) 54.6 53.6 58.2 0.336a
Pack-years mean (s.d.), median 40.1 (17.8), 34.2 40.1 (18.2), 34.2 39.9 (16.3), 34.2 0.732b
Abbreviation: s.d.¼ standard deviation. aw2-test. bMann–Whitney U-test.
Table 2 Unadjusted mean (s.d.) HRQoL scores at the four assessment
times, by baseline CT scan result (negative or indeterminate)
N T0 T1 T2 T3
630 641 620 600
Mean
(s.d.)
Mean
(s.d.)
Mean
(s.d.)
Mean
(s.d.)
SF-12 (PCS)
Total group 49.5 (8.7) 50.0 (8.2)
Negative 49.7 (8.4) 50.3 (8.3)
Indeterminate 48.5 (9.6) 48.9 (7.8)
SF-12 (MCS)
Total group 51.9 (10.3) 51.6 (11.1)
Negative 51.9 (10.2) 51.6 (11.1)
Indeterminate 51.8 (10.6) 51.9 (11.0)
EQ-5D, VAS
Total group 79.3 (13.7) 78.3 (12.9) 79.1 (12.3) 78.4 (13.7)
Negative 79.4 (13.8) 78.7 (12.6) 79.4 (12.2) 79.2 (13.4)
Indeterminate 79.1 (13.4) 76.8 (13.8) 78.3 (12.5) 75.0 (14.5)
STAI-6
Total group 33.2 (8.6) 34.6 (8.6) 32.7 (8.8) 33.0 (9.2)
Negative 33.1 (8.4) 34.4 (8.5) 32.5 (8.8) 32.6 (9.2)
Indeterminate 33.6 (9.3) 35.2 (8.9) 33.5 (8.9) 34.8 (9.2)
IES total score
Total group 4.2 (7.2) 5.9 (9.1) 4.5 (7.8) 3.6 (7.5)
Negative 4.1 (7.4) 5.8 (9.1) 4.5 (7.7) 2.4 (5.5)
Indeterminate 4.5 (6.5) 6.3 (9.1) 4.9 (8.4) 8.3 (11.3)
IES intrusive
Total group 1.8 (3.4) 2.5 (4.0) 1.8 (3.6) 1.4 (3.3)
Negative 1.7 (3.5) 2.4 (4.0) 1.8 (3.5) 0.8 (2.4)
Indeterminate 2.0 (3.0) 2.7 (4.0) 2.0 (3.8) 3.5 (5.2)
IES avoidance
Total group 2.4 (4.5) 3.5 (5.6) 2.7 (4.7) 2.2 (4.7)
Negative 2.4 (4.7) 3.4 (5.6) 2.7 (4.7) 1.5 (3.7)
Indeterminate 2.5 (4.1) 3.6 (5.7) 2.9 (4.9) 4.8 (6.9)
Abbreviations: T0¼ before trial randomisation, ie baseline HRQoL assessment;
T1¼ 1 week before the baseline CT scan; T2¼ 1 day after the baseline
CT scan; T3¼ 2 months after the baseline CT scan; s.d.¼ standard deviation;
SF-12¼ Short Form 12 (generic HRQoL); PCS¼ physical component summary;
MCS¼mental component summary; EQ-5D VAS¼ EuroQol questionnaire, visual
analogue scale; STAI-6¼ Spielberger State-Trait Anxiety Inventory 6, IES¼ Impact of
Event Scale.
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lation level due to the large numbers of subjects involved. By using
the MID criterion, we intended to provide a clue to the
meaningfulness of a statistically significant change in mean scores.
An additional reason for using the MID was the fact that this study
included large numbers of subjects and that HRQoL scale scores
do not have an intuitive interpretation. It is situation dependent
whether a statistically significant change in mean scores from, for
example 12.1 to 11.7 is to be regarded as a meaningful difference.
Remarkably, in the indeterminate result group, at all assessment
points the HRQoL scores were worse than those in the group with
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Figure 2 (A–G) Average scale scores and 95% confidence intervals per result group (negative or indeterminate baseline result) adjusted for gender, age,
education, smoking status, and smoking pack-years: SF-12 (PCS and MCS) (A and B); EQ-5D VAS (C), STAI-6 (D), and IES (total, intrusive, avoidance)
(E–G) T0, before trial randomisation; T1, just before baseline CT scan; T2, 1 day after baseline CT scan; and T3, about 2 months after baseline CT scan.
aSignificant difference. bClinically relevant difference. (A–C) A higher score indicates better HRQoL. (D–G) A lower score indicates better HRQoL.
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negative results. This was the case before the screening result was
known, and even before screening took place; however, these
differences were not statistically significant. Subjects who had a
positive baseline CT scan who completed the T0 questionnaire
(n¼ 8) reported even worse HRQoL scores before screening (data
not shown). Previous studies showed a prognostic effect of HRQoL
on survival (of lung cancer) or disease onset (Montazeri et al,
2001). Our results suggest that worse HRQoL scores before
screening may serve as a weak indicator of an indeterminate or
positive baseline scan result.
In the indeterminate group, we did not assess HRQoL after
they had received the result of the 3-month follow-up scan. This
would have provided additional information on the further
evolution of the unfavourable HRQoL scores in test indetermi-
nates, especially because the majority would have received a
negative result based on this follow-up scan. However, in our
previous study on HRQoL we found no differences between
subjects with a negative baseline CT scan and subjects with an
indeterminate follow-up scan that had a negative follow-up CT
scan (van den Bergh et al, 2008). It would have been interesting to
evaluate the HRQoL effects in subjects who received a positive test
result; however, because only 11 subjects received a positive result
at baseline, this would not provide sufficient power to give reliable
results. Moreover, because this will be a false-positive result for
some subjects, further studies are needed to determine the impact
of such a result on HRQoL.
Implications
Following the baseline scan, this led to a clinically relevant increase
in lung-cancer-specific distress in a substantial number of persons
who underwent baseline screening, although the letter to
participants clearly explained the meaning of an indeterminate
test result (i.e. a very common small abnormality). Based on recent
data from the NELSON trial and other lung cancer screening trials,
the risk of lung cancer in this group is estimated to be o2.5%
(Gohagan et al, 2004). Because distress levels may remain elevated
until the result of the follow-up CT scan is known (e.g. 3 months in
the NELSON), we recommend that the screening programme
should be improved. For example, providing information about
the small risk of having lung cancer in the letter might lead to a
reduction in the lung-cancer-specific distress. Another approach
could be to reduce the number of indeterminate test results by
identifying certain subgroup of nodules with an increased cancer
risk, or by a combination of imaging and proteomic or genomic
biomarkers.
CONCLUSIONS
This longitudinal study among participants of a lung cancer-
screening programme showed in the short term that recipients of
an indeterminate baseline screening result requiring a follow-up
CT experience an increase in lung-cancer-specific distress, whereas
the scores of recipients of a negative baseline screening result may
be interpreted as a relief.
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